Neuroanatomical basis for the antidepressant-like effects of the 5-HT1A receptor agonists 8-OH-DPAT and ipsapirone in the rat forced swimming test
Robert D. Schreiber, Jean De Vry
Abstract
Robert D. Schreiber, Jean De Vry
Abstract
In the rat forced swimming test, systemic application of the serotonin 1A (5-HT(1A)) receptor agonist 8-OH-DPAT reduced immobility (ID(50) 0.17-1.37mg/kg, depending on route of application and application schedule). Intracerebroventricular (i.c.v.) or local application into the dorsal raphe nucleus (DRN), a brain area rich in presynaptic 5-HT(1A) receptors, resulted in a parallel shift of the dose-response curve to the left (ID(50) 5.1 and 3.9µg/rat, respectively). Systemic application of the 5-HT(1A) receptor partial agonist ipsapirone resulted in a U-shaped dose-response curve (maximal effect about 30% immobility reduction at 3-10mg/kg). Local application of ipsapirone in the DRN reduced immobility (maximal effect 40% at 60µg/rat). However, 8-OH-DPAT and ipsapirone were still effective after depletion of brain 5-HT by means of 5,7-DHT (150µg, i.c.v.) or pCPA (either 2 x 150mg/kg or 2 x 350mg/kg, i.p.) Additionally, in non-lesioned rats: (1) the putative (postsynaptic) 5-HT(1A) antagonist NAN-190, but not spiperone, haloperidol, prazosin or 1-PP, was able to block the anti-immobility effects of 8-OH-DPAT in a behaviorally specific manner; (2) local application of 8-OH-DPAT and ipsapirone in the lateral septum (a brain area rich in postsynaptic 5-HT(1A) receptors) reduced immobility (8-OH-DPAT: ID(50) 11.4µg/rat; ipsapirone; maximal effect at 30µg/rat 38%); and (3) pretreatment with ipsapirone resulted in an attenuation of the effect of 8-OH-DPAT when both compounds were administered either systemically or in the lateral septum but not when both compounds were microinjected into the DRN. It is hypothesized that the anti-immobility effects of 5-HT(1A) receptor agonists are mediated by pre- and postsynaptic 5-HT(1A) receptors and that they closely reflect the intrinsic activity of these compounds at these receptors.
OpenAlex reports 55 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In the rat forced swimming test, systemic application of the serotonin 1A (5-HT(1A)) receptor agonist 8-OH-DPAT reduced immobility (ID(50) 0.17-1.37mg/kg, depending on route of application and application schedule). Intracerebroventricular (i.c.v.) or local application into the dorsal raphe nucleus (DRN), a brain area rich in presynaptic 5-HT(1A) receptors, resulted in a parallel shift of the dose-response curve to the left (ID(50) 5.1 and 3.9µg/rat, respectively). Systemic application of the 5-HT(1A) receptor partial agonist ipsapirone resulted in a U-shaped dose-response curve (maximal effect about 30% immobility reduction at 3-10mg/kg). Local application of ipsapirone in the DRN reduced immobility (maximal effect 40% at 60µg/rat). However, 8-OH-DPAT and ipsapirone were still effective after depletion of brain 5-HT by means of 5,7-DHT (150µg, i.c.v.) or pCPA (either 2 x 150mg/kg or 2 x 350mg/kg, i.p.) Additionally, in non-lesioned rats: (1) the putative (postsynaptic) 5-HT(1A) antagonist NAN-190, but not spiperone, haloperidol, prazosin or 1-PP, was able to block the anti-immobility effects of 8-OH-DPAT in a behaviorally specific manner; (2) local application of 8-OH-DPAT and ipsapirone in the lateral septum (a brain area rich in postsynaptic 5-HT(1A) receptors) reduced immobility (8-OH-DPAT: ID(50) 11.4µg/rat; ipsapirone; maximal effect at 30µg/rat 38%); and (3) pretreatment with ipsapirone resulted in an attenuation of the effect of 8-OH-DPAT when both compounds were administered either systemically or in the lateral septum but not when both compounds were microinjected into the DRN. It is hypothesized that the anti-immobility effects of 5-HT(1A) receptor agonists are mediated by pre- and postsynaptic 5-HT(1A) receptors and that they closely reflect the intrinsic activity of these compounds at these receptors.
Key concepts: Ipsapirone, 8-OH-DPAT, 5-HT1A receptor, Internal medicine, Endocrinology, Agonist, Chemistry, Dorsal raphe nucleus